Ocular Therapeutix Inc
OCUL
3.76USD+0.13 (+3.58%)Delayed as of 07 Dec 2023, 03:12 pmWatchlist
Market Summary
USD3.76+0.13
Delayedas of 07 Dec 2023, 03:12 pm3.58%
OCUL Stock Price
View Fullscreen
OCUL RSI Chart
OCUL Valuation
OCUL Price/Sales (Trailing)
OCUL Profitability
OCUL Fundamentals
OCUL Revenue
OCUL Earnings
Price Action
52 Week Range
2.577.96
(Low)(High)
Last 7 days
41.8%
Last 30 days
31.5%
Last 90 days
-5.2%
Trailing 12 Months
25.2%
How does OCUL drawdown profile look like?
OCUL Financial Health
OCUL Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2023 | 51.7M | 54.6M | 57.7M | 0 |
| 2022 | 49.4M | 49.9M | 49.7M | 51.5M |
| 2021 | 22.1M | 32.3M | 38.6M | 43.5M |
| 2020 | 6.3M | 7.3M | 12.3M | 17.4M |
| 2019 | 2.1M | 2.1M | 2.5M | 4.2M |
| 2018 | 1.8M | 2.0M | 2.0M | 2.0M |
| 2017 | 1.9M | 1.9M | 1.9M | 1.9M |
| 2016 | 1.8M | 1.8M | 1.8M | 1.9M |
| 2015 | 1.2M | 1.5M | 1.8M | 1.8M |
| 2014 | 0 | 0 | 0 | 772.0K |
| 2013 | 0 | 0 | 0 | 0 |
| 2012 | 0 | 0 | 0 | 10.0K |
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for OCUL
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Aug 30, 2023 | mattessich antony c. | bought | 24,765 | 3.81 | 6,500 | president and ceo |
| Jul 10, 2023 | graves adrienne l | acquired | - | - | 24,000 | - |
| Jul 07, 2023 | ozden rabia gurses | sold | -4,101 | 4.93 | -832 | chief medical officer |
| Jun 14, 2023 | hong seung suh | acquired | - | - | 12,000 | - |
| Jun 14, 2023 | williams leslie j. | acquired | - | - | 12,000 | - |
| Jun 14, 2023 | heier jeffrey s. | acquired | - | - | 12,000 | - |
| Jun 14, 2023 | lindstrom richard l md | acquired | - | - | 12,000 | - |
| Jun 14, 2023 | warden charles m | acquired | - | - | 12,000 | - |
| Jun 14, 2023 | raines merilee | acquired | - | - | 12,000 | - |
| Feb 06, 2023 | mattessich antony c. | sold | -83,396 | 4.24 | -19,669 | president and ceo |
Which funds bought or sold OCUL recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| Nov 27, 2023 | TRUST CO OF VERMONT | added | 25.00 | -4,940 | 15,700 | -% |
| Nov 24, 2023 | DEUTSCHE BANK AG\ | added | 19.99 | -41,553 | 112,431 | -% |
| Nov 22, 2023 | Graham Capital Management, L.P. | new | - | 299,439 | 299,439 | 0.01% |
| Nov 21, 2023 | Walleye Trading LLC | sold off | -100 | -232,793 | - | -% |
| Nov 21, 2023 | Walleye Capital LLC | sold off | -100 | -225,311 | - | -% |
| Nov 16, 2023 | Financial Gravity Asset Management, Inc. | sold off | -100 | -11.00 | - | -% |
| Nov 15, 2023 | Tudor Investment Corp Et Al | reduced | -13.28 | -489,466 | 546,884 | -% |
| Nov 15, 2023 | JANE STREET GROUP, LLC | reduced | -76.54 | -1,137,960 | 189,543 | -% |
| Nov 15, 2023 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | unchanged | - | -64,109 | 99,654 | -% |
| Nov 15, 2023 | GSA CAPITAL PARTNERS LLP | added | 96.36 | 119,000 | 733,000 | 0.06% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Ocular Therapeutix Inc
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 13, 2023 | opaleye management inc. | 7.89% | 6,075,000 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 5.16% | 3,976,853 | SC 13G/A | |
| Feb 01, 2023 | blackrock inc. | 6.4% | 4,952,737 | SC 13G/A | |
| Feb 03, 2022 | blackrock inc. | 6.7% | 5,122,835 | SC 13G/A | |
| Feb 01, 2022 | opaleye management inc. | 7.80% | 5,974,800 | SC 13G/A | |
| Feb 12, 2021 | opaleye management inc. | 8.65% | 9 | SC 13G/A | |
| Feb 02, 2021 | blackrock inc. | 7.3% | 5,512,264 | SC 13G | |
| Jun 09, 2020 | blackrock inc. | 4.8% | 3,006,167 | SC 13G/A | |
| May 21, 2020 | summer road llc | 17.0% | 11,387,656 | SC 13D/A | |
| Mar 25, 2020 | summer road llc | 18.9% | 11,024,020 | SC 13D/A |
Recent SEC filings of Ocular Therapeutix Inc
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Nov 16, 2023 | EFFECT | EFFECT | |
| Nov 07, 2023 | S-3 | S-3 | |
| Nov 07, 2023 | 8-K | Current Report | |
| Nov 07, 2023 | 10-Q | Quarterly Report | |
| Oct 04, 2023 | 8-K | Current Report | |
| Oct 03, 2023 | 8-K | Current Report | |
| Sep 13, 2023 | 8-K | Current Report | |
| Sep 05, 2023 | 4 | Insider Trading |
Peers (Alternatives to Ocular Therapeutix Inc)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
HILS | 31.4B | - | 4.92% | 426363.59% | -3.6K | 218.4K | - | -102.45% |
MRNA | 30.7B | 10.7B | 11.84% | -53.56% | -8.86 | 2.88 | -53.67% | -129.46% |
ALNY | 22.0B | 1.7B | 4.71% | -20.32% | -43.06 | 12.74 | 79.37% | 56.87% |
BMRN | 17.7B | 2.3B | 23.54% | -7.88% | 120.62 | 7.68 | 15.05% | 75.21% |
INCY | 12.4B | 3.6B | 1.56% | -32.86% | 29.22 | 3.44 | 8.35% | -51.49% |
| MID-CAP | ||||||||
APLS | 7.5B | 272.9M | 38.55% | 34.32% | -12.3 | 27.32 | 141.38% | 4.43% |
BBIO | 5.6B | - | 16.25% | 246.63% | -9.66 | 48.33 | 54.84% | -12.96% |
ACAD | 3.5B | 631.9M | -10.80% | 43.56% | -23.56 | 5.55 | 23.54% | 31.53% |
AXSM | 3.3B | 223.4M | 11.07% | -7.88% | -16.26 | 14.69 | - | -26.24% |
ARWR | 2.6B | 240.7M | -11.66% | -25.68% | -12.44 | 10.6 | -1.03% | -16.59% |
| SMALL-CAP | ||||||||
CPRX | 1.5B | 348.4M | 7.85% | -14.88% | 24.07 | 4.29 | 81.69% | -7.29% |
NVAX | 662.5M | 1.0B | -19.01% | -66.75% | -1.21 | 0.63 | -43.15% | 58.48% |
INO | 100.5M | 6.4M | -2.56% | -78.77% | -0.61 | 15.6 | -44.11% | 50.48% |
IBIO | 42.3M | - | 410.00% | -4.38% | -0.65 | - | - | -29.23% |
CRBP | 26.3M | - | 17.86% | 4717.52% | -0.55 | - | - | -13.74% |
Ocular Therapeutix Inc News
Latest updates
Financials for Ocular Therapeutix Inc
Income Statement (Last 12 Months)(In Thousands)
| Income Statement (Quarterly) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Revenue | -0.7% | 15,081 | 15,186 | 13,374 | 14,076 | 11,965 | 12,266 | 13,187 | 12,309 | 12,153 | 11,718 | 7,342 | 7,349 | 5,876 | 1,569 | 2,609 | 2,256 | 829 | 650 | 492 | 504 | 498 |
| Costs and Expenses | -4.1% | 34,295 | 35,756 | 35,923 | 33,437 | 33,509 | 32,182 | 31,020 | 30,358 | 31,682 | 31,949 | 27,570 | 21,692 | 19,882 | 19,453 | 19,223 | 23,657 | 23,973 | 22,249 | 20,150 | 17,787 | 15,314 |
| S&GA Expenses | -16.5% | 9,315 | 11,153 | 10,835 | 10,533 | 10,186 | 10,140 | 9,063 | 9,137 | 9,576 | 8,391 | 8,086 | 6,811 | 6,520 | 6,153 | 7,130 | 7,142 | 6,777 | 7,225 | 3,347 | 2,291 | 1,067 |
| R&D Expenses | -0.5% | 15,019 | 15,094 | 14,747 | 13,543 | 13,719 | 13,100 | 13,100 | 12,578 | 12,719 | 13,859 | 10,927 | 7,624 | 6,951 | 8,021 | 6,098 | 10,125 | 10,235 | 9,414 | 11,317 | 10,258 | 9,685 |
| Interest Expenses | 72.1% | 3,426 | 1,991 | 1,768 | 1,847 | 1,797 | 1,696 | 1,683 | 1,680 | 1,658 | 1,655 | 1,679 | 1,726 | 1,715 | 1,694 | 1,633 | 1,805 | 1,651 | 1,627 | 1,018 | 374 | 424 |
| Net Income | 97.5% | -516 | -20,682 | -30,318 | -15,542 | -24,188 | -18,766 | -12,542 | -3,850 | 2,657 | -8,481 | 3,121 | -85,612 | -11,944 | -36,568 | -21,512 | -26,017 | -18,778 | -24,453 | -17,124 | -17,399 | -15,010 |
| Net Income Margin | - | - | - | -1.72* | -1.38* | -1.19* | -0.65* | -0.45* | -0.15* | -2.29* | -3.19* | -5.92* | -8.94* | -7.80* | -14.16* | -14.31* | -20.43* | - | - | - | - | - |
| Free Cashflow | - | - | - | -23,352 | -19,108 | -13,963 | -11,371 | -18,876 | -15,784 | -13,258 | -20,185 | -17,517 | -6,499 | -13,872 | -14,921 | -19,103 | -20,068 | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Assets | 32.5% | 162 | 123 | 129 | 149 | 159 | 173 | 188 | 205 | 218 | 231 | 243 | 262 | 98.00 | 107 | 73.00 | 79.00 | 89.00 | 90.00 | 101 | 73.00 | 70.00 |
| Current Assets | 40.3% | 141 | 101 | 107 | 130 | 146 | 160 | 175 | 191 | 204 | 217 | 228 | 246 | 82.00 | 90.00 | 55.00 | 60.00 | 70.00 | 65.00 | 79.00 | 56.00 | 58.00 |
| Cash Equivalents | 68.6% | 112 | 67.00 | 79.00 | 102 | 121 | 135 | 145 | 166 | 179 | 192 | 209 | 228 | 71.00 | 84.00 | 48.00 | 56.00 | 65.00 | 62.00 | 76.00 | 61.00 | 57.00 |
| Inventory | 2.4% | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 |
| Net PPE | -2.6% | 12.00 | 13.00 | 12.00 | 10.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 8.00 | 8.00 | 8.00 | 9.00 | 9.00 | 10.00 | 10.00 | 11.00 | 11.00 | 10.00 | 10.00 |
| Liabilities | 29.3% | 155 | 119 | 119 | 114 | 112 | 107 | 108 | 117 | 130 | 150 | 160 | 186 | 102 | 102 | 84.00 | 82.00 | 77.00 | 81.00 | 76.00 | 37.00 | 25.00 |
| Current Liabilities | 8.4% | 35.00 | 32.00 | 30.00 | 31.00 | 29.00 | 26.00 | 24.00 | 26.00 | 25.00 | 22.00 | 27.00 | 27.00 | 23.00 | 14.00 | 11.00 | 12.00 | 11.00 | 10.00 | 9.00 | 9.00 | 13.00 |
| Shareholder's Equity | 154.4% | 8.00 | 3.00 | 10.00 | 35.00 | 46.00 | 66.00 | 80.00 | 88.00 | 87.00 | 80.00 | 83.00 | 76.00 | - | 5.00 | - | - | 11.00 | 8.00 | 26.00 | 36.00 | 46.00 |
| Retained Earnings | -0.1% | -668 | -667 | -647 | -616 | -601 | -577 | -558 | -545 | -541 | -544 | -536 | -539 | -453 | -441 | -405 | -383 | -357 | -338 | -314 | -297 | -279 |
| Additional Paid-In Capital | 0.8% | 676 | 671 | 657 | 652 | 648 | 643 | 638 | 634 | 629 | 625 | 620 | 615 | 450 | 447 | 394 | 380 | 369 | 347 | 340 | 333 | 325 |
| Shares Outstanding | 0.2% | 79.00 | 79.00 | 78.00 | 77.00 | 77.00 | 77.00 | 77.00 | 77.00 | 77.00 | 76.00 | 76.00 | 76.00 | 63.00 | 57.00 | 52.00 | 50.00 | 47.00 | 43.00 | 42.00 | 42.00 | 39.00 |
Cashflow (Last 12 Months)(In Thousands)
| Cashflow (Quarterly) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Cashflow From Operations | 61.5% | -7,732 | -20,075 | -19,973 | -16,958 | -13,169 | -10,876 | -18,600 | -15,153 | -12,982 | -20,056 | -17,359 | -6,246 | -13,658 | -14,796 | -18,854 | -19,467 | -19,544 | -19,181 | -19,386 | -13,648 | -10,873 |
| Share Based Compensation | 2.2% | 4,512 | 4,413 | 4,572 | 4,234 | 4,240 | 4,281 | 4,209 | 3,841 | 3,758 | 4,292 | 3,086 | 2,104 | 1,936 | 1,826 | 1,665 | 1,953 | 3,169 | 1,695 | 1,942 | 1,949 | 1,873 |
| Cashflow From Investing | 87.0% | -259 | -1,990 | -3,379 | -2,150 | -794 | -495 | -276 | -631 | -276 | -129 | -158 | -253 | -214 | -125 | -249 | -601 | -419 | -493 | -725 | -479 | -473 |
| Cashflow From Financing | 438.5% | 51,935 | 9,645 | 78.00 | 458 | 374 | 493 | 129 | 667 | 679 | 2,667 | -1,162 | 163,913 | 220 | 51,063 | 12,818 | 9,091 | 18,612 | 5,338 | 42,300 | 16,328 | 11,373 |
OCUL Income Statement
2023-09-30Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
| Revenue: | ||||
| Total revenue, net | $ 15,081 | $ 11,965 | $ 43,642 | $ 37,419 |
| Costs and operating expenses: | ||||
| Cost, Product and Service [Extensible List] | Product revenue, net | Product revenue, net | Product revenue, net | Product revenue, net |
| Cost of product revenue | $ 1,377 | $ 1,073 | $ 3,895 | $ 3,528 |
| Research and development | 15,019 | 13,719 | 44,860 | 39,919 |
| Selling and marketing | 9,315 | 10,186 | 31,304 | 29,390 |
| General and administrative | 8,584 | 8,531 | 25,915 | 23,875 |
| Total costs and operating expenses | 34,295 | 33,509 | 105,974 | 96,712 |
| Loss from operations | (19,214) | (21,544) | (62,332) | (59,293) |
| Other income (expense): | ||||
| Interest income | 1,212 | 285 | 2,524 | 375 |
| Interest expense | (3,426) | (1,797) | (7,187) | (5,175) |
| Change in fair value of derivative liabilities | 6,722 | (1,133) | 1,290 | 8,598 |
| Gains and losses on extinguishment of debt, net | 14,190 | 14,190 | ||
| Other income (expense), net | 1 | (1) | (1) | |
| Total other income (expense), net | 18,698 | (2,644) | 10,816 | 3,797 |
| Net loss | $ (516) | $ (24,188) | $ (51,516) | $ (55,496) |
| Net loss per share, basic | $ (0.01) | $ (0.31) | $ (0.66) | $ (0.72) |
| Weighted average common shares outstanding, basic | 79,373,272 | 76,975,839 | 78,276,341 | 76,829,434 |
| Net loss per share, diluted | $ (0.25) | $ (0.31) | $ (0.77) | $ (0.73) |
| Weighted average common shares outstanding, diluted | 85,142,504 | 76,975,839 | 84,045,573 | 82,598,666 |
| Product revenue, net | ||||
| Revenue: | ||||
| Total revenue, net | $ 14,950 | $ 11,913 | $ 43,193 | $ 36,555 |
| Collaboration revenue | ||||
| Revenue: | ||||
| Total revenue, net | $ 131 | $ 52 | $ 449 | $ 864 |
OCUL Balance Sheet
2023-09-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 110,550 | $ 102,300 |
| Accounts receivable, net | 23,589 | 21,325 |
| Inventory | 2,257 | 1,974 |
| Prepaid expenses and other current assets | 4,862 | 4,028 |
| Total current assets | 141,258 | 129,627 |
| Property and equipment, net | 12,494 | 9,856 |
| Restricted cash | 1,764 | 1,764 |
| Operating lease assets | 6,868 | 8,042 |
| Total assets | 162,384 | 149,289 |
| Current liabilities: | ||
| Accounts payable | 3,984 | 5,123 |
| Accrued expenses and other current liabilities | 28,887 | 24,097 |
| Deferred revenue | 317 | 576 |
| Operating lease liabilities | 1,878 | 1,599 |
| Total current liabilities | 35,066 | 31,395 |
| Other liabilities: | ||
| Operating lease liabilities, net of current portion | 7,251 | 8,678 |
| Derivative liabilities | 24,022 | 6,351 |
| Deferred revenue, net of current portion | 14,197 | 13,387 |
| Notes payable, net | 65,124 | 25,257 |
| Other non-current liabilities | 106 | 93 |
| Convertible Notes, net | 8,765 | 28,749 |
| Total liabilities | 154,531 | 113,910 |
| Commitments and contingencies (Note 14) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares issued or outstanding at September 30, 2023 and December 31, 2022, respectively | ||
| Common stock, $0.0001 par value; 200,000,000 shares authorized and 79,412,114 and 77,201,819 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | 8 | 8 |
| Additional paid-in capital | 676,203 | 652,213 |
| Accumulated deficit | (668,358) | (616,842) |
| Total stockholders' equity | 7,853 | 35,379 |
| Total liabilities and stockholders' equity | $ 162,384 | $ 149,289 |
| CEO | Mr. Antony Mattessich |
|---|---|
| WEBSITE | www.ocutx.com |
| EMPLOYEES | 274 |